AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca: Long-acting COVID antibody shown to prevent severe disease, death

U.S.-listed shares of AstraZeneca AZN, +0.85% gained 0.3% in premarket trading on Friday after the company said an experimental asthma drug it is developing with Amgen AMGN, -0.41% has been given an orphan drug designation as a treatment for eosinophilic esophagitis, a rare inflammatory disease. The Food and Drug Administration is expected to decide whether to approve the investigational therapy, tezepelumab, for asthma in the first three months of 2022.

AstraZeneca's experimental asthma gets an orphan drug designation for another disease

Johnson & Johnson

Moderna

Novavax

Pfizer

It'll likely push the revenue of vaccine victors even further.

What Do Mix-and-Match Doses Mean for Vaccine Stocks?

If authorized by the FDA, AstraZeneca's (AZN) AZD7442 would be the first long-acting cocktail antibody drug approved for COVID-19 prevention.

AstraZeneca (AZN) Seeks Emergency Nod for COVID Prevention Drug

AbbVie

Bristol-Myers

Gilead Sciences

GlaxoSmithKline

Eli Lilly

Sanofi

Large-cap pharmaceutical stocks offer investors stable, substantial dividends, regardless of market conditions. Here are nine that stand out.

9 Big Pharmaceutical Stocks Sporting Stellar Yields

AstraZeneca Plc (NASDAQ: AZN) has filed for an FDA Emergency Use Authorization (EUA) of AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19. The application seeks approval for AZD7442 to prevent COVID-19 for people who respond poorly to vaccines because of a weakened immune system.

AstraZeneca Seeks Emergency Use Nod For COVID-19 Drug To Prevent Infection

The company said its new drug was 77% effective in trial.

AstraZeneca Submits Covid Antibody Drug for U.S. Emergency Authorization

AstraZeneca PLC has requested authorisation in the US for emergency use of its new antibody combination to protect people with a poor immune response to vaccines against Covid-19. The drug company said its Emergency Use Authorisation (EUA) filing to the US Food and Drug Administration (FDA) included data announced in August from its PROVENT phase III trial, which showed a 77% reduction in risk of developing symptomatic COVID-19 with AZD7442, its long-acting antibody combination (LAAB).

AstraZeneca seeks emergency use authorisation for Covid-19 antibody drug in US

Late-stage trials of the drug show it is 77% effective in reducing the risk of Covid-19 symptoms if administered as a preventive treatment.

AstraZeneca Seeks Emergency Use Authorization In U.S. For Covid Prophylaxis Drug

AstraZeneca has requested US authorisation for emergency use of its new treatment to prevent COVID-19 in people who have a lessened response to vaccines because of a weakened immune system.

AstraZeneca requests emergency authoritisation for drug that reduces risk of developing COVID symptoms by 77%

AstraZeneca requests FDA emergency-use authorization for COVID-19 prophylaxis

AstraZeneca: FDA grants breakthrough-therapy designation for breast cancer drug

Reuters reported that large U.S. trial results of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease. In people aged 65 and older, the efficacy increased to 83.5%

AstraZeneca COVID-19 Jab Shows 74% Efficacy In US Trial

AstraZeneca (AZN) looks to buy full stake in Caelum Biosciences to sharpen its focus on rare-disease drugs.

AstraZeneca (AZN) to Buy Full Stake in Rare Disease Drugmaker

AstraZeneca PLC (NASDAQ:AZN) is in the spotlight today, after a large U.S. trial showed the drugmaker's Covid-19 vaccine demonstrated 74% efficacy in prevent symptomatic disease.

AstraZeneca Stock Creeps Higher on Covid-19 Vaccine Update

The COVID-19 vaccine developed by AstraZeneca PLC AZN, +3.54% AZN, +1.44% and Oxford University showed 74% efficacy at preventing symptomatic illness in a large late-stage trial conducted in the U.S., Chile and Peru, according to data published in the New England Journal Of Medicine on Thursday. The Phase 3 trial involved 32,451 participants and sought to determine the vaccine's efficacy in preventing symptomatic illness measured 15 days after the second dose.

AstraZeneca vaccine shows 74% efficacy in large Phase 3 trial in U.S., Chile and Peru: NJEM

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)

Leap Therapeutics

Leap Therapeutics Inc. ( LPTX , Financial) lived up to its name when it scored a big jump in stock price following its presentation at the recent European Society for Medical Oncology meeting. The Cambridge, Massachusetts-based microcap saw its shares climb 23% to $2.3650 after it reported new data from the study of its drug for treating gastroesophageal junction cancer.

Leap Therapeutics, AstraZeneca Shares Get Boost From Cancer Presentations

Major biotech and pharmaceutical companies such as AstraZeneca PLC (NASDAQ: AZN) and Pfizer Inc. (NYSE: PFE) have been some of the best investments to make throughout the COVID-19 pandemic.  Let's take a look at some of the major players in the biotech industry and see how they are moving today:

Why AstraZeneca And Pfizer Shares Are Moving Today

AstraZeneca Plc (NASDAQ: AZN) will take complete control of Caelum Biosciences in a deal worth up to $500 million, sharpening its focus on rare-disease drugs following its purchase of Alexion Pharmaceuticals. Caelum was founded by Fortress Biotech Inc (NASDAQ: FBIO).

AstraZeneca Buys Fortress-Biotech Founded Caelum For $500M

WILMINGTON, Del.--(BUSINESS WIRE)--Today on World Heart Day, the AstraZeneca HealthCare Foundation has awarded seven innovative, community-based nonprofit organizations $954,311 in grants across seven US states to address cardiovascular disease, a leading cause of death in the nation. The grants are part of the Foundation's signature Connections for Cardiovascular HealthSM (CCH) Next Generation program, now in its second year, which aims to improve heart health in the US, particularly among his

AstraZeneca Healthcare Foundation Awards Seven US Nonprofits More Than $900k to Improve Heart Health and Advance Health Equity

AstraZeneca plc announced that its Alexion arm has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101. The drug is being investigated to treat light chain (AL) amyloidosis, a rare disease in which abnormal proteins build up in organs throughout the body, including the heart and kidneys, causing significant organ damage and failure that can cause death.

AstraZeneca to fully acquire rare disease group Caelum Biosciences

AstraZeneca said on Wednesday its newly acquired Alexion division will purchase the remaining equity in drugmaker Caelum Biosciences in a deal that could be worth up to $500 million, expanding its access into rare-disease treatments.

AstraZeneca buys drugmaker Caelum in deal worth up to $500 million

“No good deed goes unpunished.” It's a saying that has been variously ascribed to screenwriter and director Billy Wilder, American banker Andrew Mellon and poet and playwright Oscar Wilde.

AstraZeneca: Where now for the shares and the vaccines business? And why no good deed goes unpunished

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc's (NASDAQ: AZN) Saphnelo (anifrolumab) for systemic lupus erythematosus (SLE), a serious autoimmune disease. The approval covers adult SLE patients who show insufficient response to currently available treatment.

AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan

News for AstraZeneca Stock (AZN)